Some drugs directed against markers of stem cells (like CD117, CD133, EpCAM, ALDH1) have already been tested in ovarian cancer (imatinib mesylate, ALDH1 inhibitors, modified CAR-T lymphocytes) and could probably be tested in endometriosis where stem cells are characterized by the presence of the same markers. Here, PROM1 is linked to ovarian cancer.